BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus Pharmaceuticals Inc. Myriad Genetics Inc. Neogene...
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...Robin Sawka, Biocentury Staff Former Kindred Healthcare CEO Paul Diaz has become president and CEO of Myriad Genetics Inc....
...NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus Pharmaceuticals Inc. Bicycle Therapeutics plc MiMedx Group Inc. Oasmia Pharmaceutical AB Myriad Genetics Inc. Bellerophon...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting...
BioCentury | Dec 30, 2019
Company News

FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

...patients who have not progressed on platinum chemotherapy. The agency also approved BRACAnalysis CDx from Myriad Genetics Inc....
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...products in Russia and six other countries to Stada Arzneimittel AG (Xetra:SAZ). Myriad cuts guidance Myriad Genetics Inc....
...Associate Editor BCX7353 Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad Genetics Inc. BioCryst...
BioCentury | Nov 5, 2019
Company News

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

...to relieve neuroinflammation weren’t effective. For example, EnVivo Pharmaceuticals Inc., now Forum Pharmaceutical Inc., and Myriad Genetics Inc....
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Kintai is developing tissue-targeted oral small molecules that mimic microbes’ therapeutic effects. Molecular diagnostics company Myriad Genetics Inc....
...first physician CMO of Myriad Neuroscience, which was formerly known as Assurex Health Inc. before Myriad Genetics...
...acquired the unit in 2016. Assurex’s CMO and CSO was Bryan Dechairo, who is now Myriad Genetics’...
BioCentury | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

...to catch fast-growing BRCA1 mutant ovarian cancers earlier. Whereas conventional diagnostics, such as that from Myriad Genetics Inc....
...Menlo Park, Calif. Guardant Health Inc. (NASDAQ:GH), Redwood City, Calif. Microsoft Corp. (NASDAQ:MSFT), Redmond, Wash. Myriad Genetics Inc....
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...Myriad falls on sales forecast, GeneSight concerns Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the...
...funding round from an investor consortium led by Esco. BioCentury Staff pretomanid, nitroimidazopyran (PA-824) AbbVie Inc. Akari Therapeutics plc Allergan plc Myriad Genetics Inc. ReNeuron...
BioCentury | Aug 9, 2019
Finance

Earnings on deck

...hours on U.S. exchanges Company Date Pre/post mkt 2Q19 EPS est 2Q18 EPS Expected chg Myriad Genetics Inc....
Items per page:
1 - 10 of 675
BioCentury | Oct 7, 2020
Management Tracks

CMO Noonberg enters Maze; plus Neogene, Expansion, Nkarta, Supernus and Myriad

...who is retiring. Alexander Ford has resigned as COO of Myriad Genetics Inc. (NASDAQ:MYGN). Virginia Li Maze Therapeutics Expansion Therapeutics Nkarta Inc. Supernus Pharmaceuticals Inc. Myriad Genetics Inc. Neogene...
BioCentury | Aug 15, 2020
Management Tracks

Myriad chooses Diaz as new CEO; plus changes at Novocure, Werewolf, Jasper, Avacta, Tarsus and more

...Robin Sawka, Biocentury Staff Former Kindred Healthcare CEO Paul Diaz has become president and CEO of Myriad Genetics Inc....
...NYSE:JNJ). Robin Sawka Novocure Ltd. Werewolf Therapeutics Jasper Therapeutics Inc. Avacta Group plc Tarsus Pharmaceuticals Inc. Bicycle Therapeutics plc MiMedx Group Inc. Oasmia Pharmaceutical AB Myriad Genetics Inc. Bellerophon...
BioCentury | Feb 8, 2020
Product Development

Feb. 7 Product Development Quick Takes: Myriad tumbles on revenue miss; plus Verana, Sanofi, VIB, Coda, Blueprint

...Myriad misses Street as CEO Capone departs Myriad Genetics Inc. (NASDAQ:MYGN) fell $8.27 (28%) to $21.02 after reporting...
BioCentury | Dec 30, 2019
Company News

FDA approves Lynparza as first PARP inhibitor for pancreatic cancer

...patients who have not progressed on platinum chemotherapy. The agency also approved BRACAnalysis CDx from Myriad Genetics Inc....
BioCentury | Nov 6, 2019
Company News

Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge

...products in Russia and six other countries to Stada Arzneimittel AG (Xetra:SAZ). Myriad cuts guidance Myriad Genetics Inc....
...Associate Editor BCX7353 Macrilen, macimorelin acetate (AEZS-130, ard-07, macrimorelin-ghst, EP01572, EP-1572, Solorel) University of Texas MD Anderson Cancer Center Myriad Genetics Inc. BioCryst...
BioCentury | Nov 5, 2019
Company News

Green Valley’s Alzheimer’s drug targeting gut-brain-axis gets Chinese approval

...to relieve neuroinflammation weren’t effective. For example, EnVivo Pharmaceuticals Inc., now Forum Pharmaceutical Inc., and Myriad Genetics Inc....
BioCentury | Oct 23, 2019
Company News

Management tracks: Amgen’s Meline retiring; plus BlackThorn, Rheos, Novartis, Kintai, Myriad, Avrobio, Oncorus, Moberg, Achilles and Aerpio

...Kintai is developing tissue-targeted oral small molecules that mimic microbes’ therapeutic effects. Molecular diagnostics company Myriad Genetics Inc....
...first physician CMO of Myriad Neuroscience, which was formerly known as Assurex Health Inc. before Myriad Genetics...
...acquired the unit in 2016. Assurex’s CMO and CSO was Bryan Dechairo, who is now Myriad Genetics’...
BioCentury | Aug 15, 2019
Product Development

Adaptive is surfing a wave of enthusiasm in disease detection, betting on the immune system

...to catch fast-growing BRCA1 mutant ovarian cancers earlier. Whereas conventional diagnostics, such as that from Myriad Genetics Inc....
...Menlo Park, Calif. Guardant Health Inc. (NASDAQ:GH), Redwood City, Calif. Microsoft Corp. (NASDAQ:MSFT), Redmond, Wash. Myriad Genetics Inc....
BioCentury | Aug 14, 2019
Company News

Aug. 14 Company Quick Takes: Myriad plunges on sales concerns; plus AbbVie-Allergan, TB Alliance, Akari, Carmine

...Myriad falls on sales forecast, GeneSight concerns Myriad Genetics Inc. (NASDAQ:MYGN) tumbled $19.05 (43%) to $25.50 Wednesday, the...
...funding round from an investor consortium led by Esco. BioCentury Staff pretomanid, nitroimidazopyran (PA-824) AbbVie Inc. Akari Therapeutics plc Allergan plc Myriad Genetics Inc. ReNeuron...
BioCentury | Aug 9, 2019
Finance

Earnings on deck

...hours on U.S. exchanges Company Date Pre/post mkt 2Q19 EPS est 2Q18 EPS Expected chg Myriad Genetics Inc....
Items per page:
1 - 10 of 675